搜索到 1000 条关于 카지노사이트∵Ｒｏｃ00８˛ｔＯｐ☞배팅법↑마카오슬롯오리지널■도박사이트 랭킹 포커㎞VEGAS Pro▣안전놀이터 的文章
-
-
2019.03.22 CST 专题介绍，助推细胞程序性死亡研究！（二）
speck-like proteincontain a CARD）募集半胱氨酸天冬氨酸蛋白酶酶原（pro-Caspase-1），从而形成多蛋白复合体，即炎症小体...，诱导多种 NOD 样受体（例如 NLRP3）蛋白以及 pro-IL-1β/pro-IL-18 的表达；次级信号为活化信号，细胞内的 NOD 样受体在迅速识别危险
-
2012.09.19 2010 第五届国际基因组学大会（ICG-V）
, please click: http://www.genomeconference.org/pages/Abstract.aspxTop Poster
-
2012.09.19 2012 中国医疗器械高峰论坛
trials and regulatory affairs A special showcase of top 10 Chinese innovative device companies and top 5 selected US/EU device companies interested in China
-
2012.09.19 2011年生物仿制药会议（Biosimilars Asia 2011）
时间： 2011-5-23 至 2011-5-26
地点：Grand Hyatt Shanghai
主办单位： IBC Asia (S) Pte Ltd会议简介
According to Business Insights, an estimated $25bn worth of biologics will lose patent protection by 2016, creating a significant market opportunity for biosimilars. However, the reality is that biosimilar development is a risk-fraught activity that demands significant resources in R&D, manufacturing expertise, regulatory know-how, clinical-trial capabilities, and a high level of financial investment.
Biosimilar development is riddled with complexities, ranging from regulatory, to manufacturing to marketing, and is one of the most expensive propositions in the pharmaceutical industry. It is estimated that it costs between US$100-200 million to bring a biosimilar product to market. With so much at stake, biosimilars represent not only substantial growth but equally risk..
IBC’s 2nd Annual Biosimilars Asia 2011 Summit is the ONLY conference in Asia catering to this region’s specific queries. With unprecedented insights from leading innovators and biosimilar companies, you will network and learn how to strategically position your company to maximize your ROI. Biosimilars Asia 2011 is attended by key stakeholders in the region and beyond, enabling you to make informed strategic decisions.
5 Reasons To Attend - Only conference in Asia which addresses concerns faced by the Asian biosimilar companies with experts from the region and beyond
- Learn from and personally meet senior executives from the major stakeholders amongst from biosimilar to innovator companies
- The most comprehensive event highlighting key challenges in the industry including manufacturing, marketing, pricing, transitioning from generics to biosimilars and regulatory issues
- Showcasing unique case studies from leading Asian and international biosimilar companies
- Gather the latest insights from regional biosimilar companies and MNCs about their strategic decisions and how they are positioning themselves for success
Industry Gurus / Speakers Biocon, Pfizer, Genentech, Roche, Teva, Hospira, Sandoz, Momenta, Intas, Dr Reddy’s, Shenzhen Main Luck Pharmaceuticals Past Attendees Include Vice President, ASTRAZENECA INNOVATION CENTER (China)
Senior Director, GENENTECH INC, (USA)
Managing Director, BECTON DICKINSON CO (BD BIOSCIENCES) (Singapore)
Managing Director, ASAHI GLASS CO LTD (Japan)
Deputy General Manager, SINOPHARM (China)
Head, Biotech Research, USV LTD (India)
General Manager, JCR PHARMACEUTICALS CO LTD (Japan)
Vice President, R&D/Business Development, MAIN LUCK PHARMACEUTICALS INC (China)
Senior Research Associate, HANWHA CHEMICAL (South Korea)
Vice President, BOEHRINGER INGELHEIM GMBH (Germany)
General Manager, GLAXOSMITHKLINE (CHINA) INVESTMENT CO LTD (China)
IP Director, HOSPIRA (AUSTRALIA)
President, MYCENAX BIOTECH INC (Taiwan)
Senior Director, MERCK & CO INC (USA)
Associate Director, DR REDDY''''''''S LABORATORIES LTD (India)
Chairman, SHENZHEN SCIPROGEN BIO-PHARMACEUTICAL CO LTD (SCIPROGEN) (China)COO, SHANGHAI CELGEN BIOPHARMACEUTICALS (China)
Chief Representative, TTY BIOPHARM CO LTD (Taiwan)COO, 3SBIO (China)
Project Director, JIANGSU CHIA TAI TIANQING PHARMACEUTICAL CO LTD (China)Associate Director, PFIZER INVESTMENT CO LTD (China)
General Manager, NIPPON KAYAKU CO LTD (Japan)
President, HENLIUS BIOPHARMACEUTICALS INC & SHANGHAI HENLIUS BIOTECH (USA)
Vice President, RANBAXY (USA)Registration FEES per delegate Early Bird Rate
Register & Pay before 11 March 2011Special Rate
Register & Pay before 15 April 2011Normal Rate
Register & Pay after 15 April 2011Group Rate
Group of 3 or more? US$ / CNYUS$ / CNYUS$ / CNYUS$ / CNY4 day package
(Conf + Pre & Post Workshops)2,495 /
16,6002,695 /
17,9502,895 /
19,5002,175 /
14,6503.5 day package (Conf + Workshop C & A or B ) 2,295 /
15,5002,495 /
16,6002,695 /
17,9502,025 /
13,5003 day package (Conf + Workshop A & B or C) 1,995 /
13,5002,195 /
14,6002,395 /
15,9501,795 /
12,0002.5 day package (Conf + Workshop A or B) 1,795 /
12,0001,995 /
13,5002,195 /
14,6001,695 /
10,9502 day package
(Conf only)1,495 /
9,9501,695 /
11,3001,895 /
12,6001,495 /
9,950PAYMENT TERMS
Payment must be received 10 business days prior to the event. To take advantage of discounts with an expiry cut-off date, registration and payment must be received by the cut off date.Payments by Singapore Dollars (S$)
Payments by RMB (CNY)- Payments by S$ bank draft or cheque should be made in favour of “IBC Asia (S) Pte Ltd” payable in Singapore.
- Payment by telegraphic transfer in S$ must be made to:
IBC Asia (S) Pte Ltd
A/C No.: 147-059513-001 (SGD)
The Hongkong and Shanghai Banking Corporation Limited
21 Collyer Quay, HSBC Building, Singapore 049320
Bank Swift Code: HSBCSGSG
Bank Code: 7232 - Payment by Credit Card (AMEX, VISA or MASTERCARD). Please provide your Card Number, Name of Cardholder, Expiry Date and your Signature and send it by fax to +65 6508 2407.
- Payment by telegraphic transfer in CNY must be made to:
A/C Name:
A/C No.: 720-031103-001
Beneficiary Bank:
Bank Address: No. 1000 Lujiazui Rind Road,
Pudong, Shanghai 200120, P.R. China
Bank Swift Code: HSBCCNSH
Should you be unable to attend, a substitute delegate is welcome at no extra charge. Cancellations must be received in writing at least 10 business days before the start of the event, to receive a refund less 10% processing fee per registration. The company regrets that no refund will be made available for cancellation notifications received less than 10 business days before the event.IMPORTANT NOTE:
Please quote the name of the delegate, event title and invoice number on the advice when remitting payment. Bank charges are to be deducted from participating organisations own accounts. Please fax your payment details (copy of remittance advice, cheque or draft to +65 6508 2407.
Attendance will only be permitted upon receipt of full payment. Participants wishing to register at the door are responsible to ensure all details are as published. IBC Asia will not be responsible for any event re-scheduled or cancelled.
DATA PROTECTION
The personal information entered during your registration/order, or provided by you, will be held on a database and may be shared with companies in the Informa Group in the UK and internationally. Sometimes your details may be obtained from or shared with external companies for marketing purposes. If you do not wish your details to be used for this purpose, please contact Winnie Seah (Database) on winnie.seah@ibcasia.com.sg Tel: +65 6508 2468 or Fax: +65 6508 2408.联系方式电话：+65 650 82401
-
2020.06.17 【直播 | 现场】计算机辅助设计—分子模拟与蛋白互作研讨班（8.20-22）
。【报名回执】访问此链接填写报名回执（https://www.wjx.top/jq/80710449.aspx）【咨询请联系】QQ 号：2814500767邮箱
-
2014.11.07 第十四届全国新生儿重症监护医学新进展学习班
14日举办“全国新生儿重症监护医学新进展学习班”（国家级继续教育项目2014-06-03-008（国）），届时将邀请全国知名新生儿专家授课
-
-
2017.08.13 卒中后抗血小板出血风险有多大？有这10个特征需谨慎
）（即 S2TOP-BLEED 评分模型，见表1）。表 1 预测严重出血的S2TOP-BLEED 评分（来自多变量 Cox 回归模型）具体评分方法为，根据患者临床特征评估 S2TOP-BLEED 评分列表中每一栏分值，除了年龄相关的项目外，将其他所有项目分值想加得总分，再将总分代入图 1 所示风险分布图中，得到不同
-
-
2014.12.23 远程协作治疗创伤后应激障碍
明，使用远程医疗工具，如电话，互动视频和共享电子病历进行的多学科PTSD非现场干预，即创伤后应激障碍远程医疗服务（TOP）与常规护理（UC）相比，治疗效果显著提升...包括了2009年11月至2011年9月份在CBOCs接受治疗的265名主要生活在农村的退伍军人。所有患者均符合PTSD诊断标准，他们被随机分配接受TOP治疗（N
-
-
2022.04.06 说好的 PLUS 会员来啦！说明书上传 3 月排行榜出炉
到了 825 份说明书，经过后台小助手日以继夜的审核，最终角逐出「3 月说明书上传榜」前三名：Top 1: 楠楠一沐 有效说明书 43 份Top 2: Eric_xzt 有效说明书 20 份Top 3: dxy_00wxf3se